Broadway Box-Office Analysis, Oct. 28-Nov. 3, 2013
By Robert Simonson
Playbill's newest weekly feature examines the box-office trends of the past week.
Broadway did much better this week than it did during the same seven-day period last year. It had to. There was no hurricane, after all.
The effects of Hurricane Sandy, and the cancelled performances it engendered, caused Broadway to collect only $13,578,724 from a total attendance of 149,443 theatregoers. This year, the Street could claim a collective take of $22,476,709 and 230,404 attendees.
Betrayal opened late last week to mixed-to-positive reviews. But that, of course, had no effect whatsoever on the sold-out, star-studded revival. Attendance was 100%, per usual. And the average ticket price was more than $150 — the second-most-expensive tariff in Times Square.
The effect of the reviews on the jazz revue After Midnight, which opened Nov. 3, will not be seen until next week. For the time being, however, the show is doing fine, playing to 98% capacity, if only collecting 44% of its potential box office.
In previews are the English import double-bill of Twelfth Night and Richard III, starring Mark Rylance; another double act of classics, Pinter's No Man's Land and Beckett's Waiting for Godot, starring Patrick Stewart and Ian McKellen; the new musical A Gentleman's Guide to Love and Murder; and the Lincoln Center Theater production of Macbeth.
Of these, the first attraction is presently the most popular, running up 68% of its possible monies, and playing to 95% full houses. The Pinter-Beckett repertory act comes in second, running to 90% capacity. English actors in classic plays, in seems, are a good bet this fall.
Limping along after earning less-than-stellar reviews a couple weeks back in the John Grisham adaptation A Time to Kill, which performed to auditoriums a bit more than half full. Box-office take, meanwhile, was a mere 31%, the lowest mark on Broadway save for Romeo and Juliet.
Send questions and comments to the Webmaster
Copyright © 2014 Playbill, Inc. All Rights Reserved.